10.1001/jama.2023.16620 45 SantiniS.VionnetN.PasquierJ.GonzalezRodriguezE.FragaM.PitteloudN.et al (2023)
If you've tried behavioral and environmental modifications and cold sensitivity remains bothersome, your provider may suggest an alternative compound, a slower dose escalation, or even the PlexusDx Microdose GLP-1 Protocol ($129/mo), which some patients find produces fewer temperature-related side effects while still supporting weight loss
GLOW carries no Drug Identification Number, no Natural Product Number, and no Homeopathic Drug Number, and none of the three component peptides (GHK-Cu, BPC-157, TB-500) has received market authorization for human or veterinary use in Canada
Importantly, these results are observational and should not be interpreted as medical or exercise advice
Patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 should not use this medication